We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breath Test Identifies Heart Failure in Patients

By LabMedica International staff writers
Posted on 11 Apr 2013
Acute decompensated heart failure (ADHF) is the most common indication for hospital admission, particularly in the elderly where using conventional clinical methods is unreliable.

The identification of those with impending decompensation frequently leaves insufficient lag time for therapeutic interventions, but by analyzing single puff of exhaled air from patients, it is possible to quickly determine whether they have heart failure.

Scientists at the Cleveland Clinic (Cleveland, OH, USA), collaborating with others, conducted a prospective, single-center cohort study to assess the feasibility of exhaled breath analysis to identify patients admitted for ADHF. More...
Of the 61 patients involved in the study, 25 had been hospitalized with heart failure as a primary diagnosis, 16 were healthy controls, and another 36 people were added to validate the positive research findings.

All breath analyses were performed within two hours of collection using selected ion flow tube mass spectrometry instrument (VOICE200 SIFT-MS, Syft Technologies; Christchurch, New Zealand). The investigators were able to correctly diagnose heart failure in all the patients who had been hospitalized with the disease. The breath test not only identified all the patients with heart failure, but also clearly distinguished them from cardiac cases without heart failure. The exhaled breath of patients with heart failure had considerably higher levels of organic compounds acetone and pentane, compared to those without heart failure.

Raed Dweik, MD, a pulmonologist and lead-investigator, in the Respiratory Institute at Cleveland Clinic, said, "While additional examination is needed to determine the true potential of breath analysis for heart failure identification in our patients, we're very encouraged by these results. The ability to identify patients with heart failure using a breath test has the potential for broad application due to its noninvasive nature and ease of application.” The authors concluded that future studies in exhaled breath metabolomics are needed to accelerate progress in the field of cardiovascular medicine. The study was published on April 2, 2013, in the Journal of the American College of Cardiology.

Related Links:

Cleveland Clinic
Syft Technologies




New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Gold Member
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.